title: Low relapse rate leads to high concordance of sustained virologic response (SVR) at 12 weeks with SVR at 24 weeks after treatment with ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin in subjects with chronic hepatitis C virus genotype 1 infection in the AVIATOR study.
abstract: In 247 subjects with hepatitis C virus genotype 1 infection treated with the interferon-free regimen of ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin, concordance of a sustained virologic response at 12 and 24 weeks supports the use of the earlier time point as a primary efficacy endpoint for trials of this interferon-free regimen.
authors.affiliation: Texas Liver Institute, University of Texas Health Science Center, San Antonio.
authors.forename: Fred
authors.initials: F
authors.lastname: Poordad
authors.affiliation: Institute of Liver Studies, Kings College Hospital, London, United Kingdom.
authors.forename: Kosh
authors.initials: K
authors.lastname: Agarwal
authors.affiliation: Gastro One, Germantown, Tennessee.
authors.forename: Ziad
authors.initials: Z
authors.lastname: Younes
authors.affiliation: AbbVie Inc, North Chicago, Illinois.
authors.forename: Daniel
authors.initials: D
authors.lastname: Cohen
authors.affiliation: AbbVie Inc, North Chicago, Illinois.
authors.forename: Wangang
authors.initials: W
authors.lastname: Xie
authors.affiliation: AbbVie Inc, North Chicago, Illinois.
authors.forename: Thomas
authors.initials: T
authors.lastname: Podsadecki
mesh_terms: D015081:2-Naphthylamine; D000328:Adult; D000813:Anilides / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use; D002219:Carbamates / Q000627:therapeutic use*; D003521:Cyclopropanes; D024882:Drug Resistance, Viral / Q000235:genetics; D004359:Drug Therapy, Combination; D005838:Genotype; D016174:Hepacivirus / Q000187:drug effects* / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D007372:Interferons; D047029:Lactams, Macrocyclic; D047028:Macrocyclic Compounds / Q000627:therapeutic use*; D008297:Male; D011392:Proline / Q000031:analogs & derivatives; D012367:RNA, Viral / Q000235:genetics; D012008:Recurrence; D012254:Ribavirin / Q000627:therapeutic use*; D019438:Ritonavir / Q000627:therapeutic use*; D013449:Sulfonamides / Q000627:therapeutic use*; D014498:Uracil / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014633:Valine; D019562:Viral Load
chemical_list: D000813:Anilides; D000998:Antiviral Agents; D002219:Carbamates; D003521:Cyclopropanes; D047029:Lactams, Macrocyclic; D047028:Macrocyclic Compounds; D012367:RNA, Viral; D013449:Sulfonamides; C586094:ombitasvir; D012254:Ribavirin; D014498:Uracil; D007372:Interferons; D011392:Proline; D015081:2-Naphthylamine; C588260:dasabuvir; D014633:Valine; D019438:Ritonavir; C585405:paritaprevir
keywords: concordance; direct-acting antivirals; hepatitis C; sustained virologic response